There are currently 85 clinical trials in Glendale, California looking for participants to engage in research studies. Trials are conducted at various facilities, including Glendale Adventist Medical Center, Behavioral Research Specialists, LLC, Glendale Memorial Hospital and Health Center and California Clinical Trials Medical Group. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study to Evaluate the Effects of Oral NMRA 335140 Versus Placebo in Participants With Major Depressive Disorder
NCT06029426
Recruiting
This is a randomized, double blind, placebo controlled, multi-center study to evaluate the effects of NMRA 335140 (formerly BTRX 335140) on symptoms of depression in participants with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 28 days), and a 6-week Treatment Period (during which participants will receive either NMRA 335140 or placebo). At the completion of the 6-week Treatment Period, participants who complete the study, provide informed consent, and... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
04/11/2024
Locations: Neumora Investigator Site, Glendale, California
Conditions: Major Depressive Disorder
Register for Updates
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
NCT05113251
Recruiting
This study will look at the efficacy and safety of trastuzumab deruxtecan (T-DXd) in a neoadjuvant setting, in high-risk, HER2-positive early non-metastatic breast cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/11/2024
Locations: Research Site, Glendale, California
Conditions: Breast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer
Register for Updates
AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension
NCT04499248
Recruiting
This is a multicenter, open-label, dose escalation (Cohort 1) to masked, randomized, parallel-groups (Cohort 2) and (Cohort 3) study to evaluate the safety and efficacy of AGN-193408 SR in participants with open-angle glaucoma or ocular hypertension
Gender:
All
Ages:
18 years and above
Trial Updated:
04/11/2024
Locations: Global Research Management /ID# 241699, Glendale, California
Conditions: Open-angle Glaucoma, Ocular Hypertension
Register for Updates
Investigating Geographic Atrophy Insights (i-GAIN) Natural History Study
NCT05797896
Recruiting
An observational study to investigate the natural history and evaluate biomarkers of participants with geographic atrophy secondary to age-related macular degeneration
Gender:
All
Ages:
65 years and above
Trial Updated:
04/08/2024
Locations: Global Research Management, Glendale, California
Conditions: Dry Age-related Macular Degeneration, Geographic Atrophy, Retinal Disease, Macular Degeneration, Macular Atrophy, Retinal Degeneration, Eye Diseases
Register for Updates
Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
NCT02446132
Recruiting
This is an extension study of the Phase 3 Studies 15-AVP-786-301, 15-AVP-786-302, and 17-AVP-786-305, which also allows participants from the Phase 2 Study 12-AVR-131 to be included.
Gender:
All
Ages:
Between 50 years and 90 years
Trial Updated:
04/05/2024
Locations: Behavioral Research Specialists, LLC, Glendale, California
Conditions: Agitation in Patients With Dementia of the Alzheimer's Type
Register for Updates
A Study of AMDX-2011P in Participants With CAA
NCT05709314
Recruiting
The purpose of this study is to assess safety, tolerability, plasma pharmacokinetics and biologic activity of a single intravenous dose of AMDX-2011P in participants with cerebral amyloid angiopathy (CAA).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/05/2024
Locations: Global Research Management, Glendale, California
Conditions: Cerebral Amyloid Angiopathy
Register for Updates
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (NPDR)
NCT06270836
Recruiting
This study will demonstrate that tarcocimab 5 mg is superior to sham treatment in participants with moderately severe to severe NPDR.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/04/2024
Locations: Global Research Management, Inc. - Lugene Eye Institute, Glendale, California
Conditions: Non-proliferative Diabetic Retinopathy
Register for Updates
Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum Disorder
NCT05523895
Recruiting
6-week, randomized, double-blind, fixed-dose, placebo-controlled, parallel group study in children and adolescents (aged 5 to17 years) with autism spectrum disorder (ASD) with irritability, agitation, or self-injurious behaviors to study the efficacy and safety of pimavanserin
Gender:
All
Ages:
Between 5 years and 17 years
Trial Updated:
04/04/2024
Locations: Cortica Inc. (Glendale), Glendale, California
Conditions: Irritability Associated With Autism Spectrum Disorder
Register for Updates
Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum Disorder
NCT05555615
Recruiting
52-week, open-label extension study of double-blind study ACP-103-069 to determine the long-term safety and tolerability of pimavanserin for the treatment of irritability associated with ASD in children and adolescents (aged 5 to 17 years). ACP-103-069 is a 6-week, randomized, double-blind, fixed-dose, placebo controlled, parallel group study of pimavanserin in children and adolescents with irritability associated with autism spectrum disorder (ASD).
Gender:
All
Ages:
Between 5 years and 18 years
Trial Updated:
04/04/2024
Locations: Cortica Inc. (Glendale), Glendale, California
Conditions: Irritability Associated With Autism Spectrum Disorder
Register for Updates
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer
NCT05563220
Recruiting
This is a multicenter, Phase 1b/2 trial. The phase 1b part of the trial aims to determine the RP2D of elacestrant when administered in combination with alpelisib, everolimus, palbociclib, abemaciclib, and ribociclib. The Phase 2 part of the trial will evaluate the efficacy and safety of the various combinations in patients with ER+/HER2- advanced/metastatic breast cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/04/2024
Locations: Glendale Adventist, Glendale, California
Conditions: Breast Cancer, Metastatic Breast Cancer
Register for Updates
Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-1
NCT05832931
Recruiting
This study is to evaluate the efficacy and safety of PLS240 in patients with hemodialysis-dependent end stage kidney disease (ESKD) and secondary hyperparathyroidism (SHPT). The study consists of two phases. First, a placebo-controlled, double-blind phase where patients will be randomly assigned to either receive dose-titrated PLS240 or matching placebo for 27 weeks. After the completion of the double-blind phase, patients will be eligible to enroll in the open-label extension phase, where they... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
04/03/2024
Locations: Site Number: USA030-1, Glendale, California
Conditions: Secondary Hyperparathyroidism, End-stage Kidney Disease (ESKD)
Register for Updates
Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-2
NCT05836220
Recruiting
This study is to evaluate the efficacy and safety of PLS240 in patients with hemodialysis-dependent end stage kidney disease (ESKD) and secondary hyperparathyroidism (SHPT). The study consists of two phases. First, a placebo-controlled, double-blind phase where patients will be randomly assigned to either receive dose-titrated PLS240 or matching placebo for 27 weeks. After the completion of the double-blind phase, patients will be eligible to enroll in the open-label extension phase, where they... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
04/03/2024
Locations: Site Number: USA046-2, Glendale, California
Conditions: Secondary Hyperparathyroidism, End Stage Kidney Disease
Register for Updates